Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM

被引：12
|
作者：
Devizzi, Liliana [1 ]
Guidetti, Anna [1 ]
Seregni, Ettore [1 ]
Passera, Roberto [2 ]
Maccauro, Marco [1 ]
Magni, Michele [1 ]
Testi, Adele [1 ]
Di Nicola, Massimo [1 ]
Tarella, Corrado [3 ]
Matteucci, Paola [1 ]
Viviani, Simonetta [1 ]
Ruella, Marco [3 ]
Carlo-Stella, Carmelo [4 ,5 ]
Chiesa, Carlo [1 ]
Cox, Maria Cristina [6 ]
Bombardieri, Emilio [1 ]
Gianni, Alessandro M. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Univ Turin, Turin, Italy
[3] Azienda Osped Ordine Mauriziano Umberto I, Turin, Italy
[4] Humanitas Clin & Res Ctr, Rozzano, Italy
[5] Univ Milan, Milan, Italy
[6] Univ Roma La Sapienza, Azienda Osped StAndrea, I-00185 Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 23期
关键词：
Y-90 IBRITUMOMAB TIUXETAN; FOLLOW-UP; LOW-GRADE; PHASE-II; RADIOIMMUNOTHERAPY; CHEMOTHERAPY; SAFETY; TRIAL; EFFICACY; ZEVALIN;
D O I：
10.1200/JCO.2013.50.2922
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2974 / 2976
页数：4
相关论文
共 50 条
  • [1] A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Nademanee, A
    Forman, S
    Molina, A
    Fung, H
    Smith, D
    Dagis, A
    Kwok, C
    Yamauchi, D
    Anderson, AL
    Falk, P
    Krishnan, A
    Kirschbaum, M
    Kogut, N
    Nakamura, R
    O'Donnell, M
    Parker, P
    Popplewell, L
    Pullarkat, V
    Rodriguez, R
    Sahebi, F
    Smith, E
    Snyder, D
    Stein, A
    Spielberger, R
    Zain, J
    White, C
    Raubitschek, A
    [J]. BLOOD, 2005, 106 (08) : 2896 - 2902
  • [2] High-dose myeloablative 90Y-Ibritumomab Tiuxetan radioimmunotherapy with tandem stem-cell autografting
    Bombardieri, E.
    Devizzi, L.
    Seregni, E.
    DiNicola, M.
    Carlo-Stella, C.
    Matteucci, P.
    Chiesa, C.
    Maccauro, M.
    Gianni, A. M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S195 - S195
  • [3] Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation
    Vose, Julie M.
    Bierman, Philip J.
    Loberiza, Fausto R., Jr.
    Bociek, Robert G.
    Matso, Daniel
    Armitage, James O.
    [J]. LEUKEMIA & LYMPHOMA, 2007, 48 (04) : 683 - 690
  • [4] The safety and efficacy of standard-dose 90Y ibritumomab tiuxetan combined with high-dose BEAM and autologous stem-cell transplantation in patients, including those over 60 years, with non-Hodgkin's lymphoma
    Krishnan, A
    Nademanee, A
    Forman, SJ
    Fung, H
    Molina, A
    Yamauchi, D
    Spielberger, RT
    Kogut, NM
    Raubitschek, A
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S419 - S420
  • [5] 90Y-Ibritumomab Tiuxetan as Consolidation Therapy After Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma
    Ria, Roberto
    Musto, Pellegrino
    Reale, Antonia
    Guariglia, Roberto
    Iodice, Giuseppe
    Dammacco, Franco
    Vacca, Angelo
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (06) : 891 - 895
  • [6] Updated results of high-dose yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHSCT) for poor-risk or refractory B-Cell non-hodgkin's lymphoma.
    Nademanee, Auayporn
    Raubitschek, Andrew
    Molina, Arturo
    Palmer, Joycelynne
    Tsai, Ni-Chun
    Krishnan, Amrita
    Kogut, Neil
    Forman, Stephen
    [J]. BLOOD, 2007, 110 (11) : 560A - 560A
  • [7] High-dose therapy with autologous stem-cell transplantation in aggressive non-Hodgkin's lymphoma
    Verdonck, LF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 3003 - 3003
  • [8] Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 : S145 - S145
  • [9] Ibritumomab tiuxetan combined with high-dose chemotherapy and autologous stem-cell transplantation (SCT) in patients with chemo-refractory aggressive non-Hodgkin's lymphoma.
    Shimoni, A.
    Zwass, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Nagler, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 346S - 346S
  • [10] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Scheid, C.
    Huebel, K.
    Boldt, F.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
12345